The CD may lead to therapeutic failure in patients with refractory hypothyroidism due to the impaired absorption of levothyroxine. Recently, the greatest challenge for endocrinologists regarding the treatment of refractory hypothyroid patients has been the determination of drug dosage in these cases. Recent studies reported the close association of CD with autoimmune endocrine disorders, especially autoimmune hypothyroidism (
19). According to these reports, the prevalence of occult autoimmune hypothyroidism in CD patients is higher; therefore, it seems logical to perform routine tests for checking the thyroid function among all CD patients (
20-
22).
On the other hand, some other studies evaluated the prevalence of occult CD in autoimmune thyroid diseases, namely autoimmune hypothyroidism (
23). In occult CD, where the asymptomatic condition damages small intestinal mucosa and the serology tests for autoimmunity are positive, the genetics of these cases is compatible with their disease, and they may have a normal mucosa at an earlier step while having a regular diet; nevertheless, the disease may develop later (
4,
24).
In clinical practice, the management and control of refractory hypothyroidism is a big challenge for endocrinologists, and one of the reasons could be various malabsorption disorders (
25-
27). Thyroxine malabsorption has been reported as the initial finding in patients with otherwise asymptomatic malabsorptive syndromes, especially CD (
1). Consequently, a correct diagnosis of malabsorption could be helpful in the management and control of such cases. The treatment of malabsorption would normalize or at least improve thyroxine absorption in these patients (
28).
Recently, studies have reported the high prevalence rate of undiagnosed CD patients with atypical presentations in the general population (
9,
29). Individuals with atypical manifestations may masquerade as anemia, infertility (
30), and/or osteoporosis (
1). The most prominent concomitant disease of the present study was anemia, and the most frequently reported gastrointestinal complaint was diarrhea. Unfortunately, screening these subjects has not been currently advocated. Patients with occult CD also show immunologic abnormalities, such as a positive IgA antibody, against tissue transglutaminase and endomysium or may have raising intraepithelial lymphocytes in their small intestine (
10).
The endoscopic small bowel biopsy is the gold standard test for CD diagnosis, and serologic screening tests are widely available. The detection of anti-EMA and anti-tTG antibodies by ELISA has a sensitivity range of 95 - 98% and specificity range of 94 - 95% (
31). Up to 2.6% of the results may be false negative. However, EMA and tTG are widely used for CD screening in most laboratories worldwide (
32). The most common serologic finding in the cases of the present study was raising anti-TTG and anti-EMA, respectively; nevertheless, their sensitivity and specificity were lower than those reported for usual cases (33 and 11.1% vs. 95 - 98% and 87.5% vs. 94 - 95%, respectively). Therefore, these serologic markers are less reliable for the diagnosis and screening of CD among subjects with refractory hypothyroidism.
As previously described, CD is characterized by villous atrophy and intestinal malabsorption, mainly affecting the duodenum, jejunum, and proximal ileum. As a result, these patients have a problem with the absorption of oral levothyroxine (
25). Recent studies have demonstrated patients among whom CD diagnosis was delayed, and TSH levels were persistently elevated despite increasing doses of levothyroxine. Finally, CD diagnosis in the aforementioned subjects was made, and their daily requirement of levothyroxine decreased upon the commitment to a GFD (
33).
In the upper endoscopy of the present cases, the most common findings were normal mucosa, gastritis, duodenal fissuring, duodenal atrophy, and duodenal erythema, respectively. Therefore, it is recommended to obtain duodenal biopsy specimens even from normal-looking mucosa. The most predominant pathologic report was also the presence of CD in 5 patients (mostly marsh 1 and 0 stages). The overall endoscopic view is not accurate for the diagnosis of CD among cases with refractory hypothyroidism, and it is necessary to focus on pathology reports and antibody titer (
34,
35). In case of pathology report as marsh 0 or 1 stages, it is worth mentioning to refer patients for a genetic study to confirm the diagnosis and lifelong commitment to a GFD.
However, there have been a limited number of studies evaluating this issue, regarded as the strong point of the current study, this investigation was performed as a single-center study with a small sample size, which could be considered a limitation.
4.1. Conclusion
The prevalence of CD among cases with refractory hypothyroidism is higher than that of global reports, and routine screening of CD in these patients is highly recommended even with negative serology. The sensitivity and specificity of serologic tests in hypothyroidism patients are lower than those reported for patients with normal thyroid function; this finding can encourage physicians that even in case of negative serological results evaluate patients for the possibility of CD using upper endoscopy and random duodenal biopsy. The pathology reports of marsh 0 or 1 stages are potential candidates for a genetic study to confirm the diagnosis and lifelong commitment to a GFD.